OBJECTIVE: During fall 2005, personal stockpiling of oseltamivir for use during an outbreak of H5N1 influenza virus infection was widely reported. The present study aimed to identify indications for oseltamivir prescriptions to determine whether oseltamivir that was not intended for seasonal influenza was inappropriately consumed and to compare persons who were likely to have stockpiled oseltamivir and those who did not with respect to their knowledge, understanding, concerns, and expectations regarding avian influenza. DESIGN: Survey to evaluate usage patterns for oseltamivir and assess views about avian influenza. SUBJECTS: A total of 109 outpatients who received a prescription for oseltamivir between September 1, 2005, and December 31, 2005, and 825 matched control subjects. RESULTS: Of 109 prescriptions, 36 (33.0%) were prescribed for patients with appropriate indications. Sixty-eight (62.4%) of 109 patients identified as having received oseltamivir and 440 (53.3%) of 825 individuals identified as not having received it responded to the questionnaire. Only 2 prescription recipients whose oseltamivir was not intended for immediate consumption reported that they had consumed the oseltamivir. Persons who probably intended to stockpile oseltamivir were older and more often white than those unlikely to stockpile it. They also reported greater worry about avian influenza and more often expected avian influenza to spread to the United States than those unlikely to stockpile, but there were no significant differences in responses to other questionnaire items. CONCLUSIONS: A large proportion of the oseltamivir prescriptions written in fall 2005 were probably intended for personal stockpiling. Similarities in participants' responses to questionnaire items suggest that educational campaigns may not be an effective method to curtail stockpiling of antimicrobial medications during an infectious threat. Promoting appropriate prescribing practices among providers may be a better means by which to minimize personal stockpiling.
OBJECTIVE: During fall 2005, personal stockpiling of oseltamivir for use during an outbreak of H5N1influenza virus infection was widely reported. The present study aimed to identify indications for oseltamivir prescriptions to determine whether oseltamivir that was not intended for seasonal influenza was inappropriately consumed and to compare persons who were likely to have stockpiled oseltamivir and those who did not with respect to their knowledge, understanding, concerns, and expectations regarding avian influenza. DESIGN: Survey to evaluate usage patterns for oseltamivir and assess views about avian influenza. SUBJECTS: A total of 109 outpatients who received a prescription for oseltamivir between September 1, 2005, and December 31, 2005, and 825 matched control subjects. RESULTS: Of 109 prescriptions, 36 (33.0%) were prescribed for patients with appropriate indications. Sixty-eight (62.4%) of 109 patients identified as having received oseltamivir and 440 (53.3%) of 825 individuals identified as not having received it responded to the questionnaire. Only 2 prescription recipients whose oseltamivir was not intended for immediate consumption reported that they had consumed the oseltamivir. Persons who probably intended to stockpile oseltamivir were older and more often white than those unlikely to stockpile it. They also reported greater worry about avian influenza and more often expected avian influenza to spread to the United States than those unlikely to stockpile, but there were no significant differences in responses to other questionnaire items. CONCLUSIONS: A large proportion of the oseltamivir prescriptions written in fall 2005 were probably intended for personal stockpiling. Similarities in participants' responses to questionnaire items suggest that educational campaigns may not be an effective method to curtail stockpiling of antimicrobial medications during an infectious threat. Promoting appropriate prescribing practices among providers may be a better means by which to minimize personal stockpiling.
Authors: Justin R Ortiz; David K Shay; Laura A Liedtke; Joseph S Bresee; Larry J Strausbaugh Journal: Clin Infect Dis Date: 2006-07-11 Impact factor: 9.079
Authors: Douglas Shaffer; George Armstrong; Karen Higgins; Peter Honig; Philip Coyne; Debra Boxwell; Julie Beitz; Brad Leissa; Dianne Murphy Journal: Pharmacoepidemiol Drug Saf Date: 2003 Apr-May Impact factor: 2.890
Authors: Larissa Grigoryan; Flora M Haaijer-Ruskamp; Johannes G M Burgerhof; Reli Mechtler; Reginald Deschepper; Arjana Tambic-Andrasevic; Retnosari Andrajati; Dominique L Monnet; Robert Cunney; Antonella Di Matteo; Hana Edelsein; Rolanda Valinteliene; Alaa Alkerwi; Elizabeth Scicluna; Powel Grzesiowski; Ana-Claudia Bara; Thomas Tesar; Milan Cizman; Jose Campos; Cecilia Stålsby Lundborg; Joan Birkin Journal: Emerg Infect Dis Date: 2006-03 Impact factor: 6.883
Authors: Nkuchia M M'ikanatha; Kathleen G Julian; Allen R Kunselman; Robert C Aber; James T Rankin; Ebbing Lautenbach Journal: BMC Public Health Date: 2005-01-05 Impact factor: 3.295
Authors: Esther H Fietjé; Daphne Philbert; Erica C G van Geffen; Nina A Winters; Marcel L Bouvy Journal: Emerg Infect Dis Date: 2012-03 Impact factor: 6.883
Authors: Tamasine C Grimes; Sara Garfield; Dervla Kelly; Joan Cahill; Sam Cromie; Carly Wheeler; Bryony Dean Franklin Journal: BMJ Open Date: 2020-11-24 Impact factor: 2.692